RxDoctor Payments DataLook up a doctor →

Eric Boren, MD

Allergy & Immunology · Bakersfield, CANPI 1720067598

Payments from drug & device makers

$2,406,335in general payments, 2019–2025

Across 1,133 payments — averaging $2123.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$653K
  • AstraZeneca$598K
  • Sanofi$556K
  • Teva Pharmaceuticals USA, Inc.$169K
  • Regeneron$164K
  • GSK$142K
  • plus $125K from 39 others
$6,884in research payments, 2019–2025

Across 18 payments — averaging $382.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K
  • Sanofi US Services Inc.$2K
  • Regeneron$1K

What the payments were for

  • Consulting fees$240%
  • Speaking & faculty fees$40,28273%
  • Travel & lodging$2,2594%
  • Food & beverage$12,19522%
  • Education$1700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,406,335 in reported general payments places this provider in the 95th percentile of 426 allergy & immunology providers in California.

See all allergy & immunology providers in California

Medicare billing

Part B allowed, 2024
$226,994
Medicare patients
375
Services billed
17,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab22$82,916
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$80,170
TezspireTezepelumab-Ekko13$54,780
NucalaMepolizumab11$41,544
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$16,491
Breo ElliptaFluticasone/Vilanterol16$9,542
Epinephrine24$6,630
Advair HfaFluticasone Propion/Salmeterol15$6,421
Fluticasone Propionate HfaFluticasone Propionate11$3,869
Azelastine Hcl130$3,651
Albuterol Sulfate HfaAlbuterol Sulfate107$3,468
BreynaBudesonide/Formoterol Fumarate20$2,972
Advair DiskusFluticasone Propion/Salmeterol12$2,869
SymbicortBudesonide/Formoterol Fumarate12$2,679
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta$141,589$131,257125 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$597,577$73,95142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 allergy & immunology providers in California.

Other allergy & immunology in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →